AACR: Roche's Tecentriq doesn't amp up Gilead's Yescarta in lymphoma, early study says

Gilead
Gilead's Yescarta, in tandem with Tecentriq, cleared lymphoma in 46% of phase 1/2 study patients. (Gilead China)

With a study of its Yescarta in tandem with Roche’s Tecentriq, Gilead Sciences was aiming to find out whether adding a member of the PD-1/L1 class to CAR-T treatment could improve outcomes for lymphoma patients. But after a small, early study, there’s still no evidence it can.

In a phase 1/2 study to be presented virtually at the American Association for Cancer Research annual meeting, pairing the two drugs showed a “manageable safety profile” in patients with diffuse large B-cell lymphoma (DLBCL), researchers wrote in an abstract.

But “efficacy outcomes and CAR-T cell level results” for the Yescarta-Tecentriq pairing “were similar to those of patients treated with” Yescarta alone.

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.

RELATED: ASCO: Gilead touts CAR-T franchise with Yescarta analyses, early data on pipeline drug

At the 10.2 month-mark post-treatment, 46% of patients who'd received the duo saw their cancers disappear completely. But in Zuma-1, the study that scored Yescarta its DLBCL indication, the drug cleared signs of cancer in 58% of patients.

While the trial was just a “small, open label study,” Jefferies analysts before the meeting pegged it as one to watch. “Results could provide some insight as to whether the combination of the two agents improve CAR-T persistence and disease control durability,” Biren Amin wrote in a mid-April note to clients.

RELATED: The top 15 biopharma M&A mistakes of the last decade - Gilead Sciences/Kite

But the results are likely not what the companies were hoping for as they look to expand their immuno-oncology footprints. Roche is trying to carve out its own footholds as it battles against PD-1 rivals Keytruda from Merck and Opdivo from Bristol-Myers Squibb, and Gilead is working to justify the $11.9 billion it paid to acquire Kite after striking an August 2017 tie-up agreement.